Butorov S I, Butorov I V, Bodrug N I, Krushka S I, Tofan E F
Ter Arkh. 2008;80(3):24-8.
To study effects of long-term administration of fenspiride in combination with broncholytic drugs on dynamics of clinical symptoms, external respiration function and quality of life in patients with chronic obstructive pulmonary disease (COPD).
A comparative randomized trial of fenspiride used for 6 months in combination with broncholytic drugs enrolled 68 COPD patients. A clinical status, external respiration function were examined. Quality of life was evaluated with WHO questionnaire WHOQOL-100.
Addition of fenspiride to combined treatment of COPD attenuates COPD symptoms, normalizes blood biochemistry, improves external respiration function, raises exercise tolerance. Quality of life improved by physical and mental state scales.
Fenspiride addition to COPD treatment improves efficacy of the standard treatment and is recommended for treatment of COPD of stage I and II in combination with broncholytic drugs.
研究长期服用芬司匹利联合支气管溶解药物对慢性阻塞性肺疾病(COPD)患者临床症状动态变化、肺通气功能及生活质量的影响。
一项关于芬司匹利联合支气管溶解药物使用6个月的比较随机试验纳入了68例COPD患者。检查了临床状况和肺通气功能。使用世界卫生组织生活质量问卷WHOQOL - 100评估生活质量。
在COPD联合治疗中添加芬司匹利可减轻COPD症状,使血液生化指标正常化,改善肺通气功能,提高运动耐力。生活质量在身体和精神状态量表方面得到改善。
在COPD治疗中添加芬司匹利可提高标准治疗的疗效,推荐与支气管溶解药物联合用于治疗Ⅰ期和Ⅱ期COPD。